ReviewCanadian family physician Medecin de famille canadien2013
Approach to identifying and managing atherogenic dyslipidemia: a metabolic consequence of obesity and diabetes.
Review in Canadian family physician Medecin de famille canadien, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 54 citations in OpenAlex.
- Prevalence of Statin Intolerance in a Primary Care Portuguese Population: A Retrospective Cohort Study.Journal of lipid and atherosclerosis · 2026Article
- Narrative review of metabolic syndrome and its relationships with non-alcoholic fatty liver disease, gonadal dysfunction and obstructive sleep apnea.Diabetology & metabolic syndrome · 2025Review
- Biomarker for cardiorenal syndrome risk in patients with liver cirrhosis and type 2 diabetes in Saudi Arabia.Saudi medical journal · 2024Article
- Metabolic Overlap between Alzheimer's Disease and Metabolic Syndrome Identifies theInternational journal of molecular sciences · 2023Article
- Partial Replacement of Dietary Fat with Krill Oil or Coconut Oil Alleviates Dyslipidemia by Partly Modulating Lipid Metabolism in Lipopolysaccharide-Injected Rats on a High-Fat Diet.International journal of environmental research and public health · 2022Article
- Relationship between Atherogenic Dyslipidaemia and Lipid Triad with Different Scales of Overweight and Obesity in 418,343 Spanish Workers.Journal of nutrition and metabolism · 2022Article
- Weighted gene co-expression network analysis to identify key modules and hub genes related to hyperlipidaemia.Nutrition & metabolism · 2021Article
- Allostatic load in the association of depressive symptoms with incident coronary heart disease: The Jackson Heart Study.Psychoneuroendocrinology · 2019Article
- High-Carbohydrate Diets and Food Patterns and Their Associations with Metabolic Disease in the Korean Population.Yonsei medical journal · 2018Article
- Management of Statin Intolerance in 2018: Still More Questions Than Answers.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2018Review
- Lipid parameters in obese and normal weight patients with or without chronic periodontitis.Clinical oral investigations · 2018Article
- COSMIC project: consensus on the objectives of the metabolic syndrome in clinic.Diabetes, metabolic syndrome and obesity : targets and therapy · 2018Review
- Association between single nucleotide polymorphism rs9534275 and the risk of coronary artery disease and ischemic stroke.Lipids in health and disease · 2017Article
- Discordant Lipid Pattern and Carotid Atherosclerotic Plaque. Importance of Remnant Cholesterol.Arquivos brasileiros de cardiologia · 2017Article
- High prevalence of dyslipidemia among primary care patients with hypertension and diabetes in Jamaica.Archives of medical sciences. Atherosclerotic diseases · 2017Article
- Dietary Strategies Implicated in the Prevention and Treatment of Metabolic Syndrome.International journal of molecular sciences · 2016Review
- Atherogenic Dyslipidemia and Residual Vascular Risk in Practice of Family Doctor.Medical archives (Sarajevo, Bosnia and Herzegovina) · 2015Article
- Association of waist and hip circumferences with the presence of hypertension and pre-hypertension in young South African adults.African health sciences · 2015Article
- Polymorphisms in the GCKR are associated with serum lipid traits, the risk of coronary artery disease and ischemic stroke.International journal of clinical and experimental medicine · 2015Article
- Evolution of lipid management guidelines: evidence might set you free.Canadian family physician Medecin de famille canadien · 2014Review
Corrections and comments
- Commented on by
- Commented on byResponse.2014
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo review the evidence for recognition and management of atherogenic dyslipidemia. SOURCES OF INFORMATION: High-quality randomized trials and meta-analyses were available to address most questions. North American and European guidelines were reviewed. Of these, the Canadian Cardiovascular Society lipid guidelines were most congruent with current literature. MAIN MESSAGE: Atherogenic dyslipidemia is characterized by low levels of high-density lipoprotein (HDL), high levels of triglycerides, and a high low-density lipoprotein (LDL) particle number. The condition is highly associated with cardiovascular disease (CVD) and is poorly reflected in Framingham risk score and LDL measurements. Obesity, glucose intolerance, diabetes, and metabolic syndrome are rapidly becoming more common, and are often associated with atherogenic dyslipidemia, affecting long-term CVD risk. Recognition in the office is best achieved by non-HDL or total cholesterol-HDL ratio testing. Treatment success lies in optimizing diet and exercise. Of available medications, statins produce the most benefit and can be titrated to patient tolerance rather than to LDL target levels, which have a poor evidence base. The addition of fenofibrate can be considered in patients with high triglyceride and low HDL levels who have responded poorly to or have not tolerated statins.
conclusionGrowing obesity prevalence creates a CVD risk that might be missed by LDL cholesterol testing alone. Simple calculations from results of a non-fasting lipid panel produce non-HDL levels and total cholesterol-HDL ratio, both of which are superior for predicting risk in all patients. These metrics should be available in lipid panels.
Indexed as
Identifiers
24235189PMC3828092W2123993085What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.